Compare Abeona Therapeutics Inc (ABEO) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teladoc Health Inc — how do they compare? Abeona Therapeutics Inc trades at $7.53 (market cap $421.19M), while Teladoc Health Inc trades at $6.61 (market cap $1.24B). The key difference: Teladoc Health Inc is far larger — about 2.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TDOC | |
|---|---|---|
Market Cap | $421.19M | $1.24B |
Sector | Health | Health |
52-Week High | $7.45 | $9.72 |
52-Week Low | $4.17 | $4.47 |
Enterprise Value | $276.10M | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
TDOC trades at $6.66, down 5.93% amid bearish technical signals and negative sentiment following a Q2 2026 revenue miss and lowered full-year guidance. The stock shows weak profitability with a net income margin of -7.13% but trades below book value with a P/B of 0.94. Recent news highlights multiple law firm investigations into potential securities violations, adding to investor concerns.
The outlook remains challenging with revenue pressures in the BetterHelp segment and ongoing losses, though cost controls in Integrated Care provide some support. Analyst consensus is mixed with a $8.88 price target but high hold ratings, indicating cautious optimism amid significant operational and legal risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
